New York State Teachers Retirement System Has $11.46 Million Stake in Hologic, Inc. $HOLX

Key Points

• The New York State Teachers Retirement System reduced its stake in Hologic, Inc. by 5.1%, holding approximately $11.46 million in the company's stock as of the last reporting period.
• CEO Stephen P. Macmillan sold over 138,000 shares of Hologic, resulting in a 10.08% decrease in their ownership, with the transaction valued at approximately $9.27 million.
• Analysts have provided a mixed outlook on Hologic, with an average target price of $80.15, including valuations ranging from $75.00 to $78.00 from various firms.

New York State Teachers Retirement System trimmed its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 5.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 175,919 shares of the medical equipment provider's stock after selling 9,402 shares during the period. New York State Teachers Retirement System owned approximately 0.08% of Hologic worth $11,463,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of HOLX. Chung Wu Investment Group LLC acquired a new position in shares of Hologic during the second quarter worth approximately $26,000. Zions Bancorporation National Association UT acquired a new position in shares of Hologic during the first quarter worth approximately $34,000. Cromwell Holdings LLC lifted its position in shares of Hologic by 307.0% during the second quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider's stock worth $38,000 after purchasing an additional 436 shares in the last quarter. Allworth Financial LP lifted its position in shares of Hologic by 46.0% during the first quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock worth $40,000 after purchasing an additional 216 shares in the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich acquired a new position in shares of Hologic during the first quarter worth approximately $42,000. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

HOLX has been the topic of several analyst reports. Weiss Ratings restated a "hold (c-)" rating on shares of Hologic in a report on Wednesday, October 8th. Wall Street Zen lowered shares of Hologic from a "buy" rating to a "hold" rating in a report on Wednesday, October 1st. Mizuho set a $75.00 price objective on shares of Hologic in a report on Thursday, July 31st. Evercore ISI set a $78.00 price objective on shares of Hologic and gave the company an "outperform" rating in a report on Tuesday, October 7th. Finally, Stephens restated an "overweight" rating and issued a $78.00 price objective on shares of Hologic in a report on Thursday, September 18th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $80.15.

Insiders Place Their Bets

In related news, CEO Stephen P. Macmillan sold 138,358 shares of the firm's stock in a transaction on Monday, September 22nd. The shares were sold at an average price of $66.97, for a total value of $9,265,835.26. Following the completion of the transaction, the chief executive officer owned 1,234,624 shares of the company's stock, valued at approximately $82,682,769.28. This trade represents a 10.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 1.88% of the company's stock.

Hologic Stock Up 2.0%

Shares of HOLX stock opened at $69.85 on Friday. The firm has a fifty day moving average of $67.11 and a 200-day moving average of $63.53. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 12-month low of $51.90 and a 12-month high of $84.39. The company has a market capitalization of $15.54 billion, a price-to-earnings ratio of 28.98, a P/E/G ratio of 2.40 and a beta of 0.63.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.05 by $0.03. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. During the same quarter in the prior year, the firm earned $1.06 earnings per share. The firm's revenue was up 1.2% compared to the same quarter last year. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. As a group, equities research analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.